(163 days)
Not Found
Not Found
No
The device description and performance studies focus on the chemical composition and germicidal efficacy of a disinfectant solution, with no mention of AI or ML technologies.
No.
The device is a high-level disinfectant for reprocessing medical devices, not a therapeutic device.
No
This device is a high-level disinfectant used for reprocessing heat-sensitive medical devices, not for diagnosing medical conditions.
No
The device description clearly indicates it is a chemical solution (liquid) used for disinfection, not software.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the high-level disinfection of heat-sensitive medical devices. This is a process applied to medical equipment, not a test performed on biological samples to diagnose a condition or provide information about a patient's health.
- Device Description: The description details the chemical composition and mechanism of action as a disinfectant, not as a reagent or instrument for in vitro testing.
- Performance Studies: The performance studies focus on the germicidal efficacy against various microorganisms (sporicidal, bactericidal, fungicidal, tuberculocidal, virucidal) and its effectiveness in simulated and in-use testing for disinfecting endoscopes. These are tests of the disinfectant's ability to kill microorganisms on surfaces, not tests on patient samples.
- Lack of IVD Indicators: There is no mention of analyzing biological samples, diagnosing diseases, providing information about a patient's health status, or any of the typical characteristics of an IVD.
Therefore, CIDEX® OPA Solution is a disinfectant for medical devices, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
CIDEX® OPA Solution is a high level disinfectant for reprocessing heat sensitive medical devices, for which sterilization is not suitable, and when used according to the Directions for Use.
High level disinfectant: CIDEX® OPA Solution is a high level disinfectant when used or reused, according to the Directions for Use, at or above its Minimum Effective Concentration (MEC) as determined by the CIDEX® OPA Solution Test Strips, at 20℃ (68 F) with an immersion time of at least 12 minutes for a reuse period not to exceed 14 days.
Minimum Effective Concentration (MEC): 0.3%
Product codes (comma separated list FDA assigned to the subject device)
MED
Device Description
CIDEX® OPA Solution is formulated to contain 0.55% w/v of orthophthalaldehyde. The resultant solution contains a corrosion inhibitor, chelating agents, and a dye in a phosphate buffer, ortho-Phthalaldehyde is chemically related to glutaraldehyde in that they are both aldehydes. The mechanism of action of ortho-phthalaldehyde is postulated to be similar to glutaraldehyde and is based on powerful binding of the aldehyde to the outer cell wall of the organism.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Efficacy Testing: CIDEX® OPA Solution was tested using the standard array of microbiology tests for germicidal efficacy. Tests demonstrated sporicidal, bactericidal, fungicidal, tuberculocidal and virucidal efficacy of CIDEX® OPA Solution. The CIDEX® OPA Solution used within the test protocols represented end of shelf life, reuse stressed, and MEC concentration of 0.3% conditions.
Sporicidal: CIDEX® OPA Solution is a sporicidal agent as defined by the AOAC Sporicidal Activity Test with an exposure time of at least 32 hours at 20°C.
Simulated Use: The reused and diluted CIDEX® OPA Solution at an MEC of 0.3% concentration at 20℃ is effective against Mycobacterium terrae in artificial soil.
In Use Testing: One hundred endoscopes used for bronchoscopy, gastroscopy, and colonoscopy were studied to determine the efficiency of CIDEX® OPA Solution for high level disinfection. The results support the claim of high level disinfectant for CIDEX® OPA Solution.
Biocompatibility: CIDEX® OPA Solution was evaluated for biocompatibility. The active ingredient and the formulated product were subjected to a panel of toxicologic tests, including acute oral and dermal toxicity, skin sensitization, genetic toxicity, in vitro and in vivo systems, subchronic oral toxicity and developmental toxicity tests. All animal toxicity data indicate that the product is at least as safe for human use as the predicate device.
Biocompatibility of product residues testing was conducted. Results indicate that CIDEX® OPA Solution residuals absorbed onto materials commonly used in reprocessed medical devices are at levels well below those, which cause toxic effects in animals.
Material compatibility: CIDEX® OPA Solution was evaluated for its effect on materials commonly used to fabricate medical devices. Multiple disinfection soaks over extended periods of time resulted in minimal effect on the test articles. The effects seen were similar to those seen with the predicate device.
Stability: CIDEX® OPA Solution was tested and found stable for 24 months at 15-30℃.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Minimum Effective Concentration (MEC): 0.3%
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Not Found
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 880.6885 Liquid chemical sterilants/high level disinfectants.
(a)
Identification. A liquid chemical sterilant/high level disinfectant is a germicide that is intended for use as the terminal step in processing critical and semicritical medical devices prior to patient use. Critical devices make contact with normally sterile tissue or body spaces during use. Semicritical devices make contact during use with mucous membranes or nonintact skin.(b)
Classification. Class II (special controls). Guidance on the Content and Format of Premarket Notification (510(k)) Submissions for Liquid Chemical Sterilants/High Level Disinfectants, and user information and training.
0
Page I of 4
0CT 8 1999
510(K) SUMMARY ·N.
1. 510(k) Summary of Safety and Effectiveness
| Contact | John E. Friend, R.A.C.
Vice President, Worldwide Regulatory Affairs
(949)789-3885 (Telephone)
(949) 789-3900 (Fax)
Advanced Sterilization Products
Division of Ethicon Inc.
33 Technology Drive
Irvine, Ca 92618 |
|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Date | October 6, 1999 |
| Statement | Information supporting claims of substantial equivalence, as defined
under the Federal Food, Drug and Cosmetic Act, respecting safety and
effectiveness is summarized below.
For the convenience of the Reviewer, this summary is formatted in
accordance with the Agency's final rule “...510(k) Summaries and
510(k) Statements...” (21 CFR §807) and can be used to provide a
substantial equivalence summary to anyone requesting it from the
Agency. |
| Device name | Classification: Liquid chemical germicide
Trade Name: CIDEX® OPA Solution
Proprietary Name: 0.55% ortho-phthalaldehyde Solution |
| Legally marketed device | CIDEX® OPA Solution claims equivalence to the following legally
marketed medical devices: CIDEX® Activated Dialdehyde Solution and
Peract 20. |
1
Device
Pugg 2 J
CIDEX® OPA Solution is formulated to contain 0.55% w/v of orthophthalaldehyde. The resultant solution contains a corrosion inhibitor, description chelating agents, and a dye in a phosphate buffer, ortho-Phthalaldehyde is chemically related to glutaraldehyde in that they are both aldehydes. The mechanism of action of ortho-phthalaldehyde is postulated to be similar to glutaraldehyde and is based on powerful binding of the aldehyde to the outer cell wall of the organism.
CIDEX® OPA Solution is a high level disinfectant for reprocessing heat Intended use sensitive medical devices, for which sterilization is not suitable, and when used according to the Directions for Use.
High level disinfectant: CIDEX® OPA Solution is a high level disinfectant when used or reused, according to the Directions for Use, at or above its Minimum Effective Concentration (MEC) as determined by the CIDEX® OPA Solution Test Strips, at 20℃ (68 F) with an immersion time of at least 12 minutes for a reuse period not to exceed 14 days.
Minimum Effective Concentration (MEC): 0.3%
Page 234 10/6/1999
2
page 3 of
- CIDEX® OPA Solution was tested using the standard array of Efficacy Testing microbiology tests for germicidal efficacy. Tests demonstrated sporicidal, bactericidal, fungicidal, tuberculocidal and virucidal efficacy of CIDEX® OPA Solution. The CIDEX® OPA Solution used within the test protocols represented end of shelf life, reuse stressed, and MEC concentration of 0.3% conditions.
Sporicidal: CIDEX® OPA Solution is a sporicidal agent as defined by the AOAC Sporicidal Activity Test with an exposure time of at least 32 hours at 20°C.
Simulated Use: The reused and diluted CIDEX® OPA Solution at an MEC of 0.3% concentration at 20℃ is effective against Mycobacterium terrae in artificial soil.
In Use Testing: One hundred endoscopes used for bronchoscopy, gastroscopy, and colonoscopy were studied to determine the efficiency of CIDEX® OPA Solution for high level disinfection. The results support the claim of high level disinfectant for CIDEX® OPA Solution.
CIDEX® OPA Solution was evaluated for biocompatibility. The active Biocompatibility ingredient and the formulated product were subjected to a panel of toxicologic tests, including acute oral and dermal toxicity, skin sensitization, genetic toxicity, in vitro and in vivo systems, subchronic oral toxicity and developmental toxicity tests. All animal toxicity data indicate that the product is at least as safe for human use as the predicate device.
Biocompatibility of product residues testing was conducted. Results indicate that CIDEX® OPA Solution residuals absorbed onto materials commonly used in reprocessed medical devices are at levels well below those, which cause toxic effects in animals.
Page 235 10/6/1999
3
page 4 J 4
CIDEX® OPA Solution was evaluated for its effect on materials Material commonly used to fabricate medical devices. Multiple disinfection compatibility soaks over extended periods of time resulted in minimal effect on the test articles. The effects seen were similar to those seen with the predicate device. CIDEX® OPA Solution was tested and found stable for 24 months at Stability 15-30℃. The data presented and the equivalence demonstrated to the predicate Conclusion device support the claim of substantial equivalency for CIDEX® OPA Solution. CIDEX® OPA Solution is safe and effective as a high level disinfectant when used as labeled for reprocessing heat sensitive AOAC Sporicidal Test results showed sporicidal medical devices. activity.
4
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged around the perimeter. Inside the circle is an abstract symbol that resembles an eagle or a stylized human profile, composed of three curved lines.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
8 1999 OCT
John E. Friend, M.Sc., R.Ph., R.A.C. Vice President, Worldwide Regulatory Affairs Advanced Sterilization Products® A Johnson & Johnson Company Requlatory Affairs Department Division of Ethicon, Inc. 33 Technoloqy Drive Irvine, CA 92618
Re: K991487
CIDEX® OPA Solution Trade Name: Requlatory Class: Unclassified Product Code: MED September 28, 1999 Dated: September 29, 1999 Received:
Dear Mr. Friend:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions aqainst misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) requlation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP requlation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in
5
Page 2 - Mr. Friend
the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling requlation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4692. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Timothy A. Ulatowski
Timothy A. Ulatowski Director Division of Dental, Infection Control and General Hospital Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
ADVANCED STERILIZATION PRODUCTS®
a Johnson Johnson company
REGULATORY AFFAIRS DEPARTMENT
Indications for Use
510(k) Number: K991487
Device Name: CIDEX® OPA Solution (0.55% ortho-phthalaldehyde solution)
Indications For Use:
CIDEX® OPA Solution is a high level disinfectant for reprocessing heat sensitive medical devices, and when used according to the Directions for Use.
High Level Disinfectant: CIDEX® OPA Solution is a high level disinfectant when used or reused, according to the Directions for Use, at or above its Minimum Effective Concentration (MEC) as determined by CIDEX® OPA Solution Test Strips, at 20° C (68° F) with an immersion time of at least 12 minutes for a reuse period not to exceed 14 days.
Minimum Effective Concentration (MEC): 0.3%.
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use
OR
Over-the-Counter Use X
(Optional Format 1-2-96)
Olia S. Lin
(Division Sign-Off) Division of Dental, Infection Co and General Hospita 5 1 O(k) Number